Journals / Okmeydanı Tıp Dergisi / 2017 / Cilt: 33 - Sayı: 3

Prognostic Factors and Radiotherapy in Thymic Epithelial Tumors: A Single Institutional Experience

Timik Epitelyal Tümörlerde Prognostik Faktörler ve Radyoterapinin Yeri: Tek Merkez Deneyimi

Pages
149–154
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall survival (OS) and disease free survival (DFS) were 88 months and 70 months respectively in all cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Thymic epithelial tumors (TETs) are relatively rare tumors and represent about 0.2-1.5% of all malignancies.
📊
Key Findings & Data:Aim of our study is to retrospectively evaluate the local control and survival and the factors affecting them in patients who received radiotherapy.Material and Methods: We retrospectively analysed clinical features of TET and the correlation of World Health Organisation (WHO) histologic classification and Masaoka staging system with radiotherapy modalities in 18 patients from 2004 to 2015.Results: Our patients' male/female ratio was 10/8.
💡
Conclusion & Impact:Overall survival (OS) and disease free survival (DFS) were 88 months and 70 months respectively in all cases.
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Thymic epithelial tumors (TETs) are relatively rare tumors and represent about 0.2-1.5% of all malignancies. Aim of our study is to retrospectively evaluate the local control and survival and the factors affecting them in patients who received radiotherapy.Material and Methods: We retrospectively analysed clinical features of TET and the correlation of World Health Organisation (WHO) histologic classification and Masaoka staging system with radiotherapy modalities in 18 patients from 2004 to 2015.Results: Our patients' male/female ratio was 10/8. Median age was 49 . Fifteen patients were thymoma and 3 patients were thymic carcinoma. According to Masaoka staging; patients were distributed as Stage I 5.6% (n=1), Stage II 50% (n=9), Stage III 16.7% (n=3) and Stage IV 27,7% (n=5). Overall survival (OS) and disease free survival (DFS) were 88 months and 70 months respectively in all cases. Five years OS and DFS were 45% and 50%. For Masaoka stage I-II and III-IV; OS was 99 months and 82 months (p=0.708); DFS was 96 months and 96 months (p=0.564) was found respectively. Five years OS was 50% for stage I-II and 40% for stage III-IV.Conclusion: Surgical resection is the mainstay treatment of thymomas. Adjuvant radiotherapy achieved good local control and showed an acceptable toxicity profile in patients with high-risk thymoma.

Özet

Amaç: Timik epitelyal tümörler (TET) nadir görülür ve tüm kanserlerin yaklaşık %0,2-1,5'ini oluştururlar. Bu çalışmanın amacı, radyoterapi uygulamış olduğumuz timik epitelyal tümörlü hastaların lokal kontrol ve sağkalımlarını ayrıca bunlara etki eden faktörleri incelemektir.Gereç ve Yöntem: 2004-2015 tarihleri arasında TET tanısı ile radyoterapi (RT) uyguladığımız 18 olgunun klinik özellikleri Dünya Sağlık Örgütü (DSÖ) histolojik sınıflaması ve Masoaka evreleme sistemi ile korelasyonu retrospektif olarak incelendi. Bulgular: Olgularımızın erkek/kadın oranı 10/8'dir. Ortanca yaş 49 idi. Hastaların 15'i timoma ve 3'ü timik karsinom şeklinde idi. Olgular Masaoka evrelemesine göre Evre I %5,6 (n=1), Evre II %50 (n=9), Evre III %16,7 (n=3) ve Evre IV %27,7 (n=5) şeklinde dağılmıştır. Ortalama genel sağkalım (GSK) ve hastalıksız sağkalım (HSK) tüm olgular için 88 ay ve 70 ay oldu. Beş yıllık GSK ve HSK sırasıyla %45 ve %50 oldu. Masaoka evre I-II ve III-IV için sırasıyla, GSK, 99 ay ve 82 ay (p=0,708); HSK, 96 ay ve 96 ay (p=0.564) bulundu. Beş yıllık GSK evre I-II'de %50 ve evre III-IV'de %40 olarak belirlendi.Sonuç: Timik epitelyal tümörlerde cerrahi, tedavinin esasını oluşturur. Adjuvan RT yüksek risk grubunda lokal kontrolü artırmada etkili, düşük toksisiteye sahip bir tedavi şeklidir.

🔖

Cite This Article

TEMELLİ, Ö., EKİCİ, K., KEKİLLİ, E. (2017). Prognostic Factors and Radiotherapy in Thymic Epithelial Tumors: A Single Institutional Experience. Okmeydanı Tıp Dergisi, Cilt: 33 - Sayı: 3, 149–154. https://ajindex.com/articles/291671

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy of invasive thymoma. J Clin Oncol 1990;8:1419-23.
  2. Engels EA, Pfeiffer RM. Malignant thymoma in the United States. Demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003;105:546-51.
  3. Davis RD Jr, Oldham HN Jr, Sabiston DC Jr. Primary cysts and neoplasms of the mediastinum. Recent changes in clinical presentation, methods of diagnosis, management, and results. Ann Thorac Surg 1987;44:229-37.
  4. Batata MA, Martini N, Huvos AG, et al. Thymomas. Clinicopathologic features, therapy, and prognosis. Cancer 1974;34:389-96. https://doi.org/10.1002/1097-0142(197408)34: 2_____389::AID-CNCR2820340224>3.0.CO;2-Z 5. Kundel Y, Yellin A, Popovtzer A, et al. Adjuvant radiotherapy for thymic epithelial tumor. Treatment results and prognostic factors. Am J Clin Oncol 2007;30:389-94.
  5. Proceedings of the First International Conference on Thymic Malignancies. August 20-21, 2009. Bethesda, Maryland, USA. J Thorac Oncol 2010;5:259-370
  6. Hartmann C-A, Roth C, Minck C, Niedobitek G. Thymic carcinoma: report of five cases and review of the literature. J Cancer Res Clin Oncol 1990;116:69-82.
  7. Chalabreysse L, Roy P, Cordier J-F, Loire R, Gamondes J-P, Thivolet-Bejui F. Correlation of the WHO schema for the classification of thymic epithelial neoplasms with prognosis. Am J Surg Pathol 2002;26:1605-11.
  8. Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer 1991;67:1025-32. https://doi.org/10.1002/1097-0142(19910215)67: 4_____1025::AID-CNCR2820670427>3.0.CO;2-F 10. Lewis JE, Wick MR, Scheithauer BW, Bernatz PE, Taylor WF. Thymoma. A clinicopathologic review. Cancer 1987;60(11):2727-43. https://doi.org/10.1002/1097-0142(19871201)60: 11_____2727::AID-CNCR2820601125>3.0.CO;2-D 11. Detterbeck FC, Zeeshan A. Thymoma: current diagnosis and treatment. Chin Med J (Engl) 2013;126:2186-91. 12. www.NCCN.org version 1.2016 13. www.rtog.org 2016 14. D'Angelillo RM, Trodella L, Ramella S, Cellini N,Balducci M, Mantini G, et al. Novel prognostic groups in thymic epithelial tumors: assessment of risk and therapeutic strategy selection. Int J Radiat Oncol Biol Phys 2008;71(2):420-7. https://doi.org/10.1016/j.ijrobp.2